US FDA extends prescription drug user fee act date for Alexion’s Kanuma
The previously disclosed September 8, 2015 PDUFA date has been extended by the standard extension period of three months. In response to a recent request from the FDA,
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.